Henry Schein Q3 EPS Forecast Decreased by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Zacks Research reduced their Q3 2026 earnings estimates for shares of Henry Schein in a research report issued to clients and investors on Monday, May 25th. Zacks Research analyst Team now forecasts that the company will earn $1.38 per share for the quarter, down from their prior estimate of $1.43. The consensus estimate for Henry Schein’s current full-year earnings is $5.32 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2026 earnings at $1.42 EPS, Q1 2027 earnings at $1.37 EPS, Q2 2027 earnings at $1.40 EPS, Q3 2027 earnings at $1.46 EPS and Q4 2027 earnings at $1.58 EPS.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS.

A number of other analysts also recently weighed in on the stock. Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Mizuho decreased their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company increased their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Henry Schein has an average rating of “Hold” and an average price target of $86.83.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $75.67 on Thursday. The company has a market capitalization of $8.62 billion, a PE ratio of 22.86, a P/E/G ratio of 1.85 and a beta of 0.82. The company has a 50 day simple moving average of $74.32 and a two-hundred day simple moving average of $75.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $89.29.

Hedge Funds Weigh In On Henry Schein

A number of large investors have recently modified their holdings of the company. Glenmede Trust Co. NA lifted its holdings in shares of Henry Schein by 50.6% in the 1st quarter. Glenmede Trust Co. NA now owns 8,888 shares of the company’s stock worth $655,000 after purchasing an additional 2,988 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Henry Schein by 5.9% in the 1st quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock worth $90,031,000 after purchasing an additional 68,593 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Henry Schein by 167.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock worth $69,000 after purchasing an additional 586 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Henry Schein by 16.3% in the 1st quarter. California State Teachers Retirement System now owns 123,992 shares of the company’s stock worth $9,138,000 after purchasing an additional 17,418 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Henry Schein by 15.7% in the 1st quarter. Quantinno Capital Management LP now owns 108,653 shares of the company’s stock worth $8,008,000 after purchasing an additional 14,756 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insider Activity at Henry Schein

In related news, Director William K. Daniel acquired 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director directly owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 67,565 shares of company stock worth $5,468,572. Corporate insiders own 0.89% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.